Dosing begins in trial of AlloNK, NK cell therapy for lupus nephritis
The first patient has been dosed in the U.S. as part of a clinical trial testing AlloNK, an experimental natural killer (NK) cell therapy candidate, in patients with lupus nephritis, one of the most common and severe complications of lupus. The open-label Phase 1 trial (NCT06265220) is…